| Literature DB >> 29296718 |
Beatrice Macchi1, Emanuela Balestrieri2, Caterina Frezza1,3, Sandro Grelli2, Elena Valletta1, Ambroise Marçais4,5,6, Francesca Marino-Merlo7, Jocelyn Turpin8, Charles R Bangham8, Olivier Hermine4,5,6, Antonio Mastino3,9, Ali Bazarbachi10,11.
Abstract
The therapeutic efficacy of the AZT and IFN combination in ATL presumably reflects the inhibition of RT-related functions.HTLV-1-RT activity from short-term cultured PBMCs may represent a predictive correlate of clinical response to AZT/IFN in ATL patients.Entities:
Year: 2017 PMID: 29296718 PMCID: PMC5728049 DOI: 10.1182/bloodadvances.2016001370
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529